Position in FATE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$499,500
+$277,500 QoQ
Shares Held
185,000
0.0% QoQ
Ownership
0.154%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#42
of 156 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in FATE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026BRIDGEWAY CAPITAL MANAGEMENT, LLC holds $87,985,615 across 108 Biotechnology names. FATE ranks #38 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GLUE |
Monte Rosa Therapeutics, Inc.
|
552,566 | $13,372,097 | |
| 2 | INVA |
Innoviva, Inc.
|
350,253 | $7,954,245 | |
| 3 | PBYI |
Puma Biotechnology, Inc.
|
791,616 | $6,420,005 | |
| 4 | RIGL |
Rigel Pharmaceuticals Inc
|
124,184 | $4,858,078 | |
| 5 | EXEL |
Exelixis, Inc.
|
66,100 | $3,596,501 | |
| 6 | CRMD |
CorMedix Inc.
|
434,132 | $3,407,936 | |
| 7 | KROS |
Keros Therapeutics, Inc.
|
265,017 | $2,835,681 | |
| 8 | PTCT |
Ptc Therapeutics, Inc.
|
22,000 | $1,794,540 |
All Filings in FATE
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $499,500 | 185,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $222,000 | 185,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $132,300 | 135,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $126,000 | 100,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $28,000 | 25,000 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||